Vivozon Pharma·Lunit Rally on Commercialization and Nvidia Tailwinds[K-Bio Pulse]

[Song Young Doo, Edaily Reporter] After a broad rally across Korea's pharmaceutical and biotech sector the previous day, trading on June 10 shifted toward stock specific momentum.

Vivozon Pharm surged nearly 10% on expectations for expanding prescriptions of its non opioid analgesic Anapra Injection while Lunit gained traction on growing expectations surrounding its medical AI foundation model and potential global partnerships. Investors appear increasingly focused on companies transitioning from research and development(R&D) to tangible commercialization.

Vivozon Pharm stock trend.(Source=MP DOCTOR

Vivozon Pharm Soars on Expectations for Wider Adoption of Anapra Injection

According to KG Zeroin's MP DOCTOR(formerly Market Point) Vivozon Pharm closed at 3,680 won on June 10 up 10.1%(335 won) from the previous trading day.

The primary driver behind the recent rally is the anticipated expansion of Anapra Injection the company's non opioid painkiller. On June 2 Vivazon Pharma announced an additional production order of approximately 120,000 vials in response to growing prescriptions and sales. Existing inventory has reportedly been depleted faster than expected, prompting the company to secure additional supply in advance.

The company also attributes the recent share price strength to rising demand for Anapra Injection. A Vivozon Pharm official told Edaily “The stock has continued to rise since we announced the additional production order for Anapra Injection.”

adding that “our selection for the Korea Health Industry Development Institute’s global expansion support program likely contributed as well.”

Anapra Injection is Korea’s 38th approved innovative drug and is designed as a non-opioid analgesic. It offers pain relief while reducing the risks of addiction and respiratory depression associated with conventional opioid painkillers. An investigator-initiated study conducted by researchers at Samsung Medical Center demonstrated pain-relieving efficacy comparable to opioid analgesics.

The drug has recently passed formulary reviews at major tertiary hospitals, including Samsung Medical Center and Severance Hospital, expanding its prescription base. Investors are paying close attention to whether these flagship hospital references can accelerate adoption among general hospitals and smaller regional medical centers.

The growth story extends beyond the domestic market. On June 9, Vivozon, an affiliate of Vivazon Pharma, was selected for two key programs under the Korea Health Industry Development Institute’s 2026 K-VIP(Korea Biohealth Global Expansion Support Program).

Through these programs, the company plans to strengthen its U.S. market entry strategy and global regulatory roadmap for Anapra Injection. It also aims to expand collaborations with multinational pharmaceutical companies to accelerate overseas commercialization.

Meanwhile, the high-concentration formulation of Anapra Injection recently received a patent grant decision from the Eurasian Patent Organization(EAPO), potentially strengthening barriers to entry in international markets.

The company’s oral non-opioid painkiller candidate, VVZ-2471, also received a Notice of Intention to Grant from the European Patent Office(EPO), highlighting Vivozon’s strategy to expand beyond injectable pain management into the oral analgesic market.

Industry observers view these developments as evidence that Vivozon is beginning to demonstrate tangible commercialization achievements through growing prescriptions and production expansion. Notably, the stock advanced in five of the six trading sessions between June 2 and June 10.

Lunit Gains Momentum on Nvidia Partnership Potential

Lunit was another standout performer within the healthcare sector. The company recently drew attention after being invited to Nvidia’s AI Ecosystem Roundtable held during Nvidia CEO Jensen Huang’s visit to South Korea on June 8. The invitation reinforced Lunit’s standing within the global AI ecosystem.

At the event, Lunit highlighted opportunities to expand global partnerships through its medical foundation model initiative. Industry experts view this as a sign that the company is evolving beyond a diagnostic imaging AI provider toward becoming a broader healthcare AI platform company.

A Lunit official stated, “Our invitation to Nvidia’s event appears to reflect the strong alignment between Nvidia CEO Jensen Huang’s Sovereign AI strategy and Lunit’s ongoing development of a medical science focused foundation model under national research programs.”

Nvidia has increasingly emphasized Sovereign AI as a strategic direction, while Lunit already operates national-scale cancer screening programs in more than ten countries and is conducting validation projects for healthcare-specific foundation models in both Korea and the United States.

Lunit Chief Technology Officer(CTO) Sungwon Yoo reportedly met with Nvidia executives to discuss integrating Lunit’s foundation model into Nvidia’s platform. The two sides have agreed to continue discussions through follow up meetings.

Should Lunit’s foundation model eventually be integrated into Nvidia’s platform, the company could benefit significantly from joint technology development and commercialization. Such cooperation may also create a division of roles in which Lunit focuses on algorithm development while Nvidia leverages its global distribution capabilities.

A company representative explained “Collaboration with Nvidia could accelerate technological advancement while creating a model where Lunit develops the algorithms and Nvidia handles commercialization and distribution. This structure could significantly enhance the deployment of customized foundation models tailored to individual countries and healthcare institutions.”

Lunit is already pursuing a similar collaborative framework with Microsoft. The two companies are jointly developing foundation models for integration into Microsoft’s Dragon Copilot platform. Through Microsoft Azure, healthcare providers can potentially deploy AI solutions across various hospital workflows.

Investors are paying close attention to these developments. As the medical AI industry increasingly shifts toward platform-based ecosystems, companies possessing strong datasets and algorithmic capabilities are expected to command higher valuations.

Lunit’s growing international presence also supports the investment thesis. The company continues to expand sales of its AI powered cancer diagnostic solutions across the United States, Japan, and Europe, while actively exploring opportunities in the Middle East. Potential collaborations with global AI leaders such as Nvidia could create meaningful synergies not only in technology development but also in market expansion.